Mechanistic insights into propolis in targeting adipokines including leptin, resistin, and adiponectin: A systematic review
- 10 January 2026
- journal article
- review article
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (1) , 31
Abstract
Background Propolis is a bioactive bee product that may influence adipokines involved in metabolic and inflammatory disorders; however, findings on leptin, adiponectin, and resistin are inconsistent across models and human studies. Current study aimed to systematically synthesize preclinical and clinical evidence on the effects of propolis and propolis-derived compounds on leptin, adiponectin, and resistin, and to summarize proposed mechanistic pathways. Methods The study protocol was registered in PROSPERO (CRD42024593198). We searched PubMed, Web of Science, Scopus, and Google Scholar to find related articles published between 1900 and 2025. We screened reference lists, and used alert services after the primary search. We included in vitro, animal, and human studies that were published in English language and evaluated propolis/propolis-derived compounds versus a comparator and reporting leptin, adiponectin, and resistin outcomes. Risk of bias was assessed using the CRIS guideline (in vitro), SYRCLE tool (animal), and Cochrane risk-of-bias tool (clinical trials). Findings were synthesized narratively due to heterogeneity. Results Twenty-six studies were included (9 in vitro, 11 animals, 6 human). In vitro studies generally reported decreased leptin and resistin expression and increased adiponectin expression following propolis-derived phenolics; one study reported increased leptin mRNA with a Brazilian propolis extract. In animal studies, leptin decreased in 5/8 studies and adiponectin increased in 5/9 studies, while remaining studies reported no change or opposite directions. Human trials showed mixed results: leptin decreased in 1/2 trials and adiponectin increased in 2/5 trials, whereas other trials reported no significant change. Substantial heterogeneity in propolis type/origin, formulation, dose, duration, and participant health status limited comparability. Conclusions Preclinical evidence suggests that propolis and selected constituents can modulate adipokines (often lowering leptin/resistin and increasing adiponectin), but clinical evidence is limited and inconsistent. Well-designed, adequately powered trials using standardized propolis preparations are required to clarify efficacy and translational relevance.Keywords
Funding Information
- Tabriz University of Medical Sciences
This publication has 47 references indexed in Scilit:
- SYRCLE’s risk of bias tool for animal studiesBMC Medical Research Methodology, 2014
- Caffeic acid phenethyl ester reduces the activation of the nuclear factor κB pathway by high-fat diet-induced obesity in miceMetabolism, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Brazilian propolis-derived components inhibit TNF-α-mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytesBiochimica et Biophysica Acta (BBA) - General Subjects, 2011
- Artepillin C, as a PPARγ ligand, enhances adipocyte differentiation and glucose uptake in 3T3-L1 cellsBiochemical Pharmacology, 2011
- Caffeic Acid Phenethyl Ester Suppresses the Production of Adipocytokines, Leptin, Tumor Necrosis Factor -Alpha and Resistin, during Differentiation to Adipocytes in 3T3-L1 CellsBiological and Pharmaceutical Bulletin, 2011
- Ethanolic extracts of Brazilian red propolis promote adipocyte differentiation through PPARγ activationPhytomedicine, 2010
- Propolis Prevents Diet-Induced Hyperlipidemia and Mitigates Weight Gain in Diet-Induced Obesity in MiceBiological and Pharmaceutical Bulletin, 2009
- Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss studyEuropean Journal of Endocrinology, 2008
- Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonistsJournal of Clinical Investigation, 2000